← All trials
NCT04924322
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Apr 30, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jun 11, 2021
- Last posted
- Oct 1, 2021
- Enrollment
- 258
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- University of ColoradoCollaborator
- Yale UniversityOverall official - principal investigator
- University of PennsylvaniaCollaborator
- Medical College of WisconsinCollaborator
- University of IowaCollaborator
- Virginia Commonwealth UniversityCollaborator
- University of CincinnatiCollaborator
- Ohio State UniversityCollaborator
- New York Presbyterian HospitalCollaborator
- Pennsylvania State UniversityCollaborator
- Emory UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- Washington University in St. LouisCollaborator
- Golisano Children's HospitalCollaborator
- Maria Fareri Children's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.